title: When to discontinue treatment of prolactinoma?
authors.affiliation: Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism Churchill Hospital, Oxford OX3 7LJ, UK. john.wass@noc.anglox.nhs.uk
authors.forename: John Ah
authors.initials: JA
authors.lastname: Wass
mesh_terms: D018491:Dopamine Agonists / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods / Q000592:standards; D006801:Humans; D010911:Pituitary Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D011388:Prolactin / Q000097:blood; D015175:Prolactinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors
chemical_list: D018491:Dopamine Agonists; D011388:Prolactin